|
Miltenyi Biotec
flt3 ligand Flt3 Ligand, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Human+Flt3-Ligand%2C+research+grade/pmc07116590-643-60-63 Average 95 stars, based on 1 article reviews
flt3 ligand - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
R&D Systems
fms like tyrosine kinase 3 ligand Fms Like Tyrosine Kinase 3 Ligand, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Recombinant+Human+Flt-3+Ligand%2FFLT3L+Protein/pm37058769-85-35-41 Average 95 stars, based on 1 article reviews
fms like tyrosine kinase 3 ligand - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
R&D Systems
feline flt3 ligand flt3l Feline Flt3 Ligand Flt3l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Recombinant+Feline+Flt-3+Ligand%2FFLT3L+Protein%2C+CF/pmc02839791-60-40-43 Average 90 stars, based on 1 article reviews
feline flt3 ligand flt3l - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
R&D Systems
mouse flt3l Mouse Flt3l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Mouse+Flt-3+Ligand%2FFLT3L+(NP_038548%2E3)+VersaClone+cDNA/pm38351322-306-43-53 Average 92 stars, based on 1 article reviews
mouse flt3l - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant murine flt3 l Recombinant Murine Flt3 L, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Recombinant+Human+Flt-3+Ligand%2FFLT3L+Protein%2C+CF/pm17081781-142-36-42 Average 91 stars, based on 1 article reviews
recombinant murine flt3 l - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant mouse flt3 ligand rmflt3l Recombinant Mouse Flt3 Ligand Rmflt3l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Recombinant+Mouse+Flt-3+Ligand%2FFLT3L+Protein/bio_rxiv__2025__03__05__641591-209-25-30 Average 93 stars, based on 1 article reviews
recombinant mouse flt3 ligand rmflt3l - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
R&D Systems
flt 3 ligand Flt 3 Ligand, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Recombinant+Mouse+Flt-3+Ligand%2FFLT3L+Protein%2C+CF/pmc10838547-30-14-18 Average 93 stars, based on 1 article reviews
flt 3 ligand - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Novus Biologicals
a2f10 A2f10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Flt-3%2FFlk-2%2FCD135+Antibody+(A2F10)+%5BDyLight+680%5D/10__7554_slash_elife__74561-186-74-72 Average 91 stars, based on 1 article reviews
a2f10 - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
antibodies against flrt3 ![]() Antibodies Against Flrt3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/FLT3+Rabbit+mAb/pmc11885377-118-10-15 Average 95 stars, based on 1 article reviews
antibodies against flrt3 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
primary antibodies against p flt3 ![]() Primary Antibodies Against P Flt3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Phospho-FLT3+(Tyr591)+Mouse+mAb/pm38037057-97-7-13 Average 92 stars, based on 1 article reviews
primary antibodies against p flt3 - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
phospho flt3 ![]() Phospho Flt3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Phospho-FLT3+(Tyr589%2F591)+Rabbit+mAb/10__1158_slash_1078___0432__ccr___13___2052-40-9-24 Average 94 stars, based on 1 article reviews
phospho flt3 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti phospho flt3 tyr591 antibody ![]() Anti Phospho Flt3 Tyr591 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/flt3/Phospho-FLT3+(Tyr591)+Antibody/pm16091740-172-3-21 Average 93 stars, based on 1 article reviews
anti phospho flt3 tyr591 antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: The shRNA sequences used in this study
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: shRNA, Control
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: of FLRT3 ameliorates lung vascular permeability induced by lung I/R. Mouse left lungs were subjected to 60 min ischemia via helium clamp followed by different durations of reperfusion (R60 min, R120 min, and R240 min). A Western blot analysis revealed decreased FLRT3 protein levels at 60 and 120 min post-reperfusion. B Double immunofluorescence staining showed FLRT3 (green) co-localized with CD31 (red) in pulmonary vessels and decreased after I/R. Scale bar, 50 μm. C Western blot confirmed successful FLRT3 restoration in mice receiving LV-FLRT3 compared to LV-Control. D H&E staining showed FLRT3 overexpression attenuated I/R-induced tissue damage and inflammatory infiltration. E Immunohistochemical staining of cleaved caspase 3 demonstrated reduced apoptosis with FLRT3 overexpression. Scale bar, 50 μm. F Blood gas analysis revealed improved PaO 2 /FiO 2 ratio with FLRT3 overexpression. G Wet-to-dry ratio measurement showed decreased pulmonary edema with FLRT3 overexpression). H Evans blue extravasation assay demonstrated preserved vascular barrier function with FLRT3 overexpression. I TEM imaging revealed maintained endothelial cell–cell junctions in FLRT3-overexpressing mice. Data are presented as mean ± SD. n = 5 per group. Statistical significance was determined using unpaired Student’s t test to compare two groups, and one-way ANOVA and Tukey’s multiple comparisons tests to compare multiple groups. * P < 0.05, ** P < 0.01 compared with the indicated groups.
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Permeability, Western Blot, Double Immunofluorescence Staining, Control, Staining, Over Expression, Immunohistochemical staining, Imaging
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: Overexpression of FLRT3 promotes cell migration and rescues H/R-induced cell death and inhibition on cell migration. HPMECs were transduced with LV-Control, LV-FLRT3, sh-Control or sh-FLRT3 for 48 h. A Western blot confirmed successful FLRT3 overexpression and knockdown in HPMECs. B CCK-8 assay showed FLRT3 manipulation did not affect baseline cell viability. C Wound healing assay (24 h) demonstrated enhanced migration in LV-FLRT3 group and reduced migration in sh-FLRT3 group. D Transwell migration assay validated the migration changes with FLRT3 manipulation. E Western blot showed LV-FLRT3 restored H/R-induced FLRT3 reduction. F CCK-8 assay revealed FLRT3 overexpression protected against H/R-induced viability decrease. G Wound healing assay demonstrated FLRT3 overexpression preserved migration capacity under H/R conditions. H Transwell assay confirmed the protective effect of FLRT3 on H/R-impaired cell migration. Data are mean ± SD ( n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test to compare multiple groups. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Over Expression, Migration, Inhibition, Transduction, Control, Western Blot, Knockdown, CCK-8 Assay, Wound Healing Assay, Transwell Migration Assay, Transwell Assay
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: FLRT3 overexpression increases endothelial barrier integrity via cytoskeletal remodeling and restoration of cell–cell junctions after H/R. HPMECs were transduced with LV-Control or LV-FLRT3 for 48 h, then subjected to H/R. A TEER measurements showed FLRT3 overexpression prevented H/R-induced barrier dysfunction. B Evans blue permeability assay demonstrated FLRT3 overexpression reduced H/R-induced barrier leakage. C F-actin staining (FITC-phalloidin, green; DAPI, blue) revealed FLRT3 overexpression maintained cytoskeletal organization under H/R. Scale bar, 50 μm. D Western blot showed FLRT3 overexpression preserved junction protein levels after H/R. E VE-cadherin immunofluorescence demonstrated maintained adherens junctions with FLRT3 overexpression during H/R. Scale bar, 50 μm. F Claudin-5 immunofluorescence showed preserved tight junction organization with FLRT3 overexpression after H/R. Data are mean ± SD ( n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Over Expression, Transduction, Control, Permeability, Staining, Western Blot, Immunofluorescence
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: The FLRT3 protein is destabilized through the autophagic–lysosomal pathway after H/R. A qRT-PCR revealed unchanged FLRT3 mRNA levels in HPMECs after H/R ( n = 3/group). B qRT-PCR showed stable FLRT3 mRNA levels in lung tissue after I/R ( n = 5/group). C , D Protein stability assay using CHX (20 μg/ml) demonstrated accelerated FLRT3 degradation in H/R-treated HPMECs, with significant reduction at 2 h post-CHX ( n = 3/group). E Western blot showed proteasome inhibitor MG132 (5 μM) failed to prevent H/R-induced FLRT3 degradation ( n = 3/group). F Lysosomal inhibitors NH 4 Cl (10 µM) and CQ (10 μM) restored FLRT3 levels in H/R-treated HPMECs. Western blot quantification showed significant restoration of FLRT3 levels with both inhibitors ( n = 3/group). G Autophagy inhibitor Baf-A1 (100 nM) increased both LC3-II/LC3-I ratio and FLRT3 levels under H/R conditions ( n = 3/group). Data are presented as mean ± SD. Statistical significance was determined using unpaired Student’s t test to compare two groups and one-way ANOVA and Tukey’s multiple comparisons test to compare multiple groups. Two‐way ANOVA with Tukey’s post hoc test was used to compare multiple groups with two categorical variables. ** P < 0.01 compared with the indicated groups. Baf-A1 Bafilomycin-A1, CHX cycloheximide, CQ chloroquine, NH 4 Cl ammonium chloride
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Quantitative RT-PCR, Stability Assay, Western Blot
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: RND3 is a target of FLRT3. A HumanBase Gene Networks analysis predicted functional correlation between FLRT3 and RND3 in lung tissue. B Co-IP assay demonstrated endogenous FLRT3–RND3 protein interaction in HPMECs, with input and IgG controls confirming specificity. C GST pulldown assay validated direct FLRT3-RND3 binding. D Double immunofluorescence (FLRT3-red, RND3-green) showed protein co-localization in HPMECs. Scale bar, 50 μm. E Western blot revealed FLRT3 overexpression increased RND3 levels while FLRT3 knockdown reduced RND3 expression. F Western blot showed FLRT3 overexpression restored H/R-induced RND3 reduction ( P < 0.01). Data are mean ± SD ( n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Functional Assay, Co-Immunoprecipitation Assay, GST Pulldown Assay, Binding Assay, Immunofluorescence, Western Blot, Over Expression, Knockdown, Expressing
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: RND3 is required for FLRT3 overexpression related cytoprotective effects after H/R in HPMEC cells. H/R-induced HPMECs were transduced with LV-FLRT3 and/or sh-RND3. A Western blot showed that overexpression of FLRT3 led to an increase in RND3 protein expression, while knockdown of RND3 in FLRT3-overexpressing HPMECs resulted in a reduction in RND3 protein expression levels. B , C Western blot showed RND3 knockdown reversed FLRT3-mediated protein expression under H/R. D TEER measurements revealed RND3 knockdown compromised FLRT3’s barrier-protective effect. E Evans blue assay validated RND3’s requirement in FLRT3-mediated barrier protection. F F-actin staining (phalloidin, green; DAPI, blue) showed RND3 knockdown prevented FLRT3’s cytoskeletal preservation. Scale bar, 50 μm. G Western blot demonstrated RND3 knockdown reversed FLRT3’s protection of junction proteins (VE-cadherin, ZO-1, claudin-5, and occludin). H , I Immunofluorescence of VE-cadherin ( H ) and claudin-5 ( I ) confirmed RND3’s role in FLRT3-mediated junction maintenance. Scale bar, 50 μm. Data are mean ± SD ( n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Over Expression, Transduction, Western Blot, Expressing, Knockdown, Evans Blue Assay, Staining, Preserving, Immunofluorescence
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: Activation of RhoA kinase reduced FLRT3 overexpression related cytoprotective effects induced by H/R in HPMEC cells. A RhoA-GTP pulldown assay and Western blot showed FLRT3 overexpression reduced H/R-induced RhoA pathway activation (RhoA-GTP, p-MYPT1/MYPT1, p-MLC/MLC). B Pull-down assay and western blot analysis demonstrated RND3 knockdown reversed FLRT3’s suppression of RhoA signaling under H/R. C Wound healing assay showed RhoA activator U-46619 blocked FLRT3’s migration-protective effect. D Transwell assay confirmed U-46619’s inhibition of FLRT3-mediated migration protection. E TEER measurements revealed U-46619 prevented FLRT3’s barrier-protective effect. F Evans blue assay validated U-46619’s disruption of FLRT3-mediated barrier protection. G F-actin staining (phalloidin, green; DAPI, blue) showed U-46619 prevented FLRT3’s cytoskeletal preservation. Scale bar, 50 μm. H , I Immunofluorescence of VE-cadherin ( H ) and claudin-5 ( I ) demonstrated U-46619 abolished FLRT3’s junction protection. Data are mean ± SD ( n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Activation Assay, Over Expression, Western Blot, Pull Down Assay, Knockdown, Wound Healing Assay, Migration, Transwell Assay, Inhibition, Evans Blue Assay, Disruption, Staining, Preserving, Immunofluorescence
Journal: Lung
Article Title: FLRT3 Overexpression Attenuates Ischemia–Reperfusion Induced Vascular Hyperpermeability and Lung Injury Through RND3
doi: 10.1007/s00408-025-00791-w
Figure Lengend Snippet: Knockdown RND3 reduces FLRT3 overexpression related protective effects on I/R-induced lung injury in mice. A-C Analysis of lung tissue from mice receiving LV-FLRT3 via tail vein 3 days prior to I/R (60 min ischemia, 120 min reperfusion). A Western blot showing increased RND3 protein expression following FLRT3 overexpression. B Western blot demonstrating FLRT3-mediated restoration of junction proteins (VE-cadherin, claudin-5, ZO-1, and occludin). C Pull-down assay and western blot showing FLRT3-mediated suppression of RhoA pathway activation. D – J Analysis of lung tissue from mice treated with both LV-FLRT3 and sh-RND3 via tail vein 3 days before I/R surgery: D H&E staining showed RND3 knockdown reversed FLRT3’s protection against tissue injury (quantified by injury scores). Scale bar, 50 μm. E Cleaved-caspase 3 immunohistochemistry demonstrated compromised anti-apoptotic effects. Scale bar, 50 μm. F – H I/R injury and vascular permeability revealed RND3 knockdown abolished FLRT3’s protection via PaO 2 /FiO 2 ratio ( F ), Lung wet/dry ratio ( G ), Evans blue extravasation ( H ). I TEM showed impaired endothelial junction preservation. J RhoA activity assays demonstrated restored RhoA pathway activation (RhoA-GTP, p-MYPT1, p-MLC). Data are mean ± SD ( n = 5/group). * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the indicated groups
Article Snippet: Protein was extracted using lysis buffer, and incubated with primary
Techniques: Knockdown, Over Expression, Western Blot, Expressing, Pull Down Assay, Activation Assay, Staining, Immunohistochemistry, Permeability, Preserving, Activity Assay
Journal: Cancer cell international
Article Title: GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
doi: 10.1186/s12935-023-03142-y
Figure Lengend Snippet: Fig. 1 GNF-7 potently inhibited the proliferation of FLT3-ITD AML cells and targeted FLT3-ITD downstream signaling pathways. A AML cell line MOLM-13, MV4-11, U937 and THP-1 were treated with DMSO or increasing concentrations of GNF-7 for 48 h and the normalized cell proliferation was measured by CellTiter Glo assay. B Mononuclear cells isolated from umbilical cord blood (Normal #1, Normal #2), bone marrow of diagnosed with AML (AML #1, AML #2) and AML harboring FLT3-ITD mutation (AML #3, AML #4, AML #5) were treated with different concentrations of GNF-7 for 48 h, and normalized cell proliferation was detected by CellTiter Glo assay. C Primary bone marrow cells isolated from AML #3 and AML #4 were exposed to GNF-7 for 4 h and then detected by western blotting with antibodies against phosphorylated and total of FLT3, Stat5, AKT and ERK, respectively. D Phosphorylated and total of FLT3, Stat5, AKT and ERK in MOLM-13 and MV4-11 cells treated with GNF-7 for 4 h were detected by western blotting. E Dose response curve of GNF-7 on Ba/F3 FLT3-ITD cells in the presence or absence of IL-3. F Ba/F3 FLT3-ITD cells were treated with the different concentration of GNF-7 for 4 h and subjected to western blotting with the indicated antibodies. All experiments were repeated three times with the same results. Data are presented as mean ± SD, and P values were calculated using Student t test. *p < 0.05, ** p < 0.01, and *** p < 0.001
Article Snippet: The membrane was then blotted with specific
Techniques: Protein-Protein interactions, Glo Assay, Isolation, Mutagenesis, Western Blot, Concentration Assay
Journal: Cancer cell international
Article Title: GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
doi: 10.1186/s12935-023-03142-y
Figure Lengend Snippet: Fig. 2 GNF-7 interacts with FLT3 protein. A Docking model of FLT3 bound to GNF-7: the yellow dotted line represents the hydrogen bond interaction, the green line represents the amino acid that forms hydrogen bonds with GNF-7, the cartoon represents the FLT3 protein, and the purple stick represents the GNF-7 molecule. B 2D interaction diagram of the FLT3/GNF-7 complex: GNF-7 is bound to the FLT3 protein in a pocket surrounded by LYS706, TYR696, GLY697, CYS694, ALA642, LEU818, PHE830, VAL624, LEU616, CYS695, and SER705 amino acids, GNF-7 forms hydrogen bonds with SER705 and forms hydrophobic interaction with LYS706, TYR696, GLY697, CYS694, ALA642, LEU818, PHE830, VAL624, LEU616, CYS695. C, E Thermal stabilization of FLT3 in Ba/F3 FLT3-ITD cells treated with GNF-7 (1 μM) or DMSO in various temperatures (C) and treated with various concentrations of GNF-7 (E) was analyzed through CETSA assay. D–F The density of the FLT3 bands were quantified by quantity one software. All experiments were repeated three times with the same results. Data are presented as mean ± SD, and P values were calculated using Student t test. * p < 0.05, ** p < 0.01, and *** p < 0.001
Article Snippet: The membrane was then blotted with specific
Techniques: Software
Journal: Cancer cell international
Article Title: GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
doi: 10.1186/s12935-023-03142-y
Figure Lengend Snippet: Fig. 3 GNF-7 showed significant therapy effect on the mice model engrafted with Ba/F3 FLT3-ITD cells. A The mice engrafted with Ba/F3 FLT3-ITD cells were treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg) for 8 days and the percentages of leukemia cells infiltrated in peripheral blood were then analyzed by flow cytometry. B The mice engrafted with Ba/F3 FLT3-ITD cells were treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg) for 9 days and the percentages of leukemia cells infiltrated in bone marrow were then analyzed by flow cytometry. C The spleen weight in each group were measured. D The survival curve of mice was calculated. Data are presented as mean ± SD, and P values were calculated using Student t test. * p < 0.05, ** p < 0.01, and *** p < 0.001
Article Snippet: The membrane was then blotted with specific
Techniques: Flow Cytometry
Journal: Cancer cell international
Article Title: GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
doi: 10.1186/s12935-023-03142-y
Figure Lengend Snippet: Fig. 4 Activity of GNF-7 against drug resistant Ba/F3 FLT3-ITD/F691L cells. A Relative proliferation of Ba/F3 populations stably expressing FLT3-ITD mutant isoforms after 48 h in various concentrations of GNF-7 were measured by CellTiter Glo assay. B IC50 values of Ba/F3 stably expressing FLT3-ITD and FLT3-ITD/F691L cells treated with various concentrations of AC220, gilteritinib and GNF-7 were analyzed by CellTiter Glo assay. C After treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg) for 8 days, the percentages of leukemia cells infiltrated in peripheral blood of mice (n = 6) engrafted with Ba/F3 FLT3-ITD/F691L cells were evaluated by flow cytometry. D After treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg) for 9 days, the burden of leukemia cells in bone marrow of mice (n = 3) which was randomly selected from each group were detected. E The spleen weights were analyzed. F The Kaplan–Meier survival curves of animal survival of mice treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg). All cell line experiments were repeated three times with the same results. P values were calculated by log-rank test and shown. Data are presented as mean ± SD, and P values were calculated using Student t test. * p < 0.05, ** p < 0.01, and *** p < 0.001
Article Snippet: The membrane was then blotted with specific
Techniques: Activity Assay, Stable Transfection, Expressing, Mutagenesis, Glo Assay, Flow Cytometry
Journal: Cancer cell international
Article Title: GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
doi: 10.1186/s12935-023-03142-y
Figure Lengend Snippet: Fig. 5 GNF-7 exerts potent therapy effect on AML PDX model. A, B Primary patient cells from AML #3 or AML #4 carrying with FLT3-ITD were transplanted into busulfan pretreated NOG mice and then randomly divided into three groups. Peripheral blood of 5 mice administrated with vehicle, 15 mg/kg GNF-7 and 30 mg/kg Gilteritinib were collected at the indicated time, and the leukemia cells content was detected by flow cytometry using human CD45 antibody. C, D The percentages of leukemia stem and progenitor cells in peripheral blood were detected by flow cytometry using human CD45 and CD34 antibodies. E, F The Kaplan–Meier survival curves of animal survival of mice treated with vehicle, AC220 (10 mg/kg), gilteritinib (30 mg/kg) and GNF-7 (15 mg/kg)
Article Snippet: The membrane was then blotted with specific
Techniques: Flow Cytometry
Journal: Clinical Cancer Research
Article Title: Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
doi: 10.1158/1078-0432.ccr-13-2052
Figure Lengend Snippet: Figure 1. Acquired point mutations of FLT3 TKDs are associated with sorafenib resistance. A, cDNA- based mutation analysis was performed using cDNA sequencing with multiple primers in sorafenib- resistant cells (Ba/F3-ITD-Res) and parental cells Ba/F3-ITD. B, engineered cells with point mutations were exposed to varying concentrations of sorafenib for 48 hours, and apoptosis induction and cell-growth inhibition were assessed as the percentage of annexin V–positive cells by flow cytometry and by counting the numbers of viable cells using the Trypan blue dye exclusion method, respectively. Growth inhibition was expressed as percentage relative to that in the control group. Data are the mean of 3 independent determinations. C, resistant cells and their parental cells Ba/F3-ITD were treated with sorafenib for 2 hours, and phosphorylation levels of FLT3 and its downstream proteins were measured by immunoblot analysis. The ratios are semiquantitative analyses indicating the expression levels of phosphorylated proteins compared with their total proteins and normalized to the first control lane, which was defined as 1. Sora, sorafenib; p-, phosphorylated.
Article Snippet: Rabbit polyclonal antibodies were purchased from the following sources:
Techniques: Mutagenesis, Sequencing, Inhibition, Cytometry, Control, Phospho-proteomics, Western Blot, Expressing
Journal: Clinical Cancer Research
Article Title: Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
doi: 10.1158/1078-0432.ccr-13-2052
Figure Lengend Snippet: Figure 2. Type I kinase inhibitors retain sensitivity to sorafenib-resistant cells. A, sorafenib-resistant cells were exposed to the indicated concentrations of AC220 for 48 hours and apoptosis induction and cell-growth inhibition were measured by flow cytometry and Trypan blue dye exclusion method, respectively. B, sensitivity of resistant cells and their parental Ba/F3-ITD cells to the indicated inhibitor was assessed as described in Fig. 1. C, sensitivity of novel type I inhibitor crenolanib to sorafenib-resistant cells was assessed by exposing the cells in crenolanib for 72 hours as described in Fig. 1B. D, phosphorylation levels of FLT3 and its downstream proteins ERK and AKT were determined by immunoblot analysis after 24 hours of treatment with crenolanib. The ratios of semiquantitative analyses indicated the expression levels of phosphorylated proteins to their respective total proteins or housekeeping protein GAPDH.
Article Snippet: Rabbit polyclonal antibodies were purchased from the following sources:
Techniques: Inhibition, Cytometry, Phospho-proteomics, Western Blot, Expressing
Journal: Clinical Cancer Research
Article Title: Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
doi: 10.1158/1078-0432.ccr-13-2052
Figure Lengend Snippet: Figure 3. Combination of type I and type II kinase inhibitors or 2 type I inhibitors shows synergistic proapoptotic effects in sorafenib-resistant FLT3-mutant cell lines. A, the sorafenib-resistant and parental cells were treated with a combination of crenolanib and sorafenib at indicated concentrations for 48 hours. Apoptosis induction was determined as described in Fig. 1B. , P < 0.01, , P < 0.001. B, the modulation of correlative proteins was determined by using immunoblot analysis after 1 hour of single-agent/combination treatments. C, FLT3 with ITD plus Y842C mutant protein was isolated using immunoprecipitation (IP) with anti-FLT3 antibodies and in vitro kinase assay was performed in the presence/absence of crenolanib (0.5 mmol/L) and/or sorafenib (0.5 mmol/L). Phosphorylation levels of FLT3 were determined by anti- phospho-FLT3 antibodies using immunoblotting. D, sorafenib-resistant cells Ba/F3-ITDþ676/842 were treated with indicated single or multiple agents for 48 hours. Apoptosis induction was determined as described in Fig. 1B. creno, crenolanib; , P < 0.05; , P < 0.01; , P < 0.001.
Article Snippet: Rabbit polyclonal antibodies were purchased from the following sources:
Techniques: Mutagenesis, Western Blot, Isolation, Immunoprecipitation, In Vitro, Kinase Assay, Phospho-proteomics
Journal: Clinical Cancer Research
Article Title: Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
doi: 10.1158/1078-0432.ccr-13-2052
Figure Lengend Snippet: Figure 5. Combination of crenolanib with sorafenib demonstrates synergistic/additive proapoptotic effects in primary human AML cells with FLT3 ITD mutations in vitro. A, primary AML mononuclear cells were exposed to the indicated agents for 48 hours and apoptosis induction was determined as described in Fig. 1B after gating on CD34 or CD33 positive populations. B, relevant proteins were analyzed by immunoblot analysis after treating the primary AML cells with indicated agents for 16 hours. The ratios of semiquantitative analyses indicated the expression levels of phosphorylated proteins to their respective total proteins or housekeeping protein GAPDH.
Article Snippet: Rabbit polyclonal antibodies were purchased from the following sources:
Techniques: In Vitro, Western Blot, Expressing
Journal: Oncogene
Article Title: Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.
doi: 10.1038/sj.onc.1208957
Figure Lengend Snippet: Figure 3 Effects of Tyr796Phe, Tyr892Phe, Tyr845Phe and Tyr922Phe on the constitutive activation of mFLT3Asp838Val in Ba/F3 cells. (a) Surface expression of mFLT3 mutants on Ba/F3 cell lines. Comparable expressions of mutant mFLT3 on cell surface were confirmed by flow cytometry. (b) mFLT3 was immunoprecipitated with anti-mFLT3 antibody from lysates of Ba/F3 cells stably expressing Tyr-Phe mutants of mFLT3Asp838Val with or without FLT3 ligand (FL), and immunoblotted with anti-phosphotyrosine antibody (upper lanes) and with anti-mFLT3 (lower lanes). (c) The immunoprecipitates that was similarly prepared as (b) were also subjected to immunoblotting with anti- phospho-FLT3 (Tyr591) monoclonal antibody (upper lanes) and with anti-mFLT3 (lower lanes). This monoclonal antibody against phospho-FLT3 detects FLT3 only when phosphorylated at tyrosine at codon 592 of mFLT3. The relative phosphorylation rate of each FLT3 mutant was assessed by chemical image analyzer and expressed as the ratio of the phosphorylation rate of each mutant compared with that of mFLT3Asp838Val. These results are representative of three independent experiments
Article Snippet: Antiphosphotyrosine antibody (P-Tyr-100),
Techniques: Activation Assay, Expressing, Mutagenesis, Cytometry, Immunoprecipitation, Stable Transfection, Western Blot, Phospho-proteomics